Bao 2020.

Methods	Study design: randomised clinical trial Study duration: February 2018 to February 2020 Duration of follow‐up: 1 month Setting: hospital
Participants	Number of participants: 54 Inclusion criteria: diagnosed as HCC; intermediate‐ or advanced‐stage Age (mean ± SD, range ): TACE + RFA: 59.87 ± 5.20 years, 21‐73 years; TACE alone: 59.15 ± 6.75 years, 40‐73 years Male (n/total): TACE + RFA: 14/27; TACE alone: 15/27
Interventions	TACE + RFA group (n = 27): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: theprubicin 20‐30g, cisplatin 80 mg RFA: the interval between TACE and RFA was 2 weeks. Output power of 150 W Control group (n = 27): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: theprubicin 20‐30g, cisplatin 80 mg
Outcomes	Tumour response: measured by contrast‐enhanced CT according to WHO criteria Tumour diameter: measured by CT images Adverse events Liver function: measured by blood testing
Notes	Country of study: China Source of funding: none There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.